Anti-HER-2 engineering antibody ChA21 inhibits growth and induces apoptosis of SK-OV-3 cells

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Anti-HER-2 antibodies exhibit diverse biological functions based on their targeted epitopes.
• The engineered antibody ChA21 binds to subdomain I of the HER-2 extracellular domain.
• Ovarian carcinoma cell line SK-OV-3 overexpresses HER-2.

Purpose of the Study:

• To investigate the effects of ChA21 on the growth and apoptosis of HER-2-overexpressing SK-OV-3 cells.
• To evaluate the in vitro and in vivo efficacy of ChA21.
• To elucidate the molecular mechanisms underlying ChA21's anti-cancer activity.

Main Methods:

• Cell proliferation assessed using MTT assay.
• Apoptosis detected via TUNEL staining, transmission electron microscopy, and flow cytometry.
• Expression of apoptosis-related proteins Bax and Bcl-2 analyzed by immunohistochemistry.

Main Results:

• ChA21 treatment resulted in dose-dependent inhibition of cell proliferation in vitro.
• Significant tumor growth inhibition observed in vivo following ChA21 therapy.
• ChA21 therapy increased apoptosis induction and upregulated Bax expression while downregulating Bcl-2 expression.

Conclusions:

• ChA21 demonstrates significant anti-proliferative and pro-apoptotic effects on SK-OV-3 cells.
• The mechanism involves regulating the balance between Bax and Bcl-2 protein expression.
• ChA21 holds potential as a therapeutic agent for HER-2-positive ovarian cancer.